This message was sent to ##Email##
|
|
|
|
| |
Healio
A study of patients hospitalized with COVID-19 across the United States showed little difference in outcomes between solid organ transplant recipients and the general population.
“Previously published studies focusing on SOT patients and COVID-19 lack comparison with a control group to ascertain their risk as compared to the general population,” Miklos Z. Molnar, MD, PhD, of the James D. Eason Transplant Institute at Methodist University Hospital in Memphis, and colleagues wrote.
READ MORE
Clinical Transplantation
The SARS‐CoV‐2 pandemic poses unique and unprecedented challenges to patients, providers, and healthcare systems. COVID‐19 appears to be high‐risk in patients with cardiovascular disease as well as those on immunosuppressive agents in the setting of organ transplantation. Patients with COVID‐19 have been shown to develop acute myocarditis, characterized by either viral or immune‐mediated cardiac injury.
READ MORE
|
Promoted by
|
|
|
|
 |
American Journal of Transplantation
Kidney transplant program performance in the United States is commonly measured by post‐transplant outcomes. Inclusion of pre‐transplant measures could provide a more comprehensive assessment of transplant program performance and necessary information for patient decision‐making. In this study, researchers propose a new metric, the waitlisting rate, defined as the ratio of patients' waitlisted in a center relative to the person‐years referred for evaluation to a program.
READ MORE
Cancer Network
Though further research is necessary, researchers suggested that immune checkpoint inhibitors can be used as an individualized therapy in certain patients who have undergone solid organ transplantation. However, researchers indicated that additional research is necessary to determine the most effective use of these agents to further improve outcomes.
READ MORE
 |
|
Promoted by
Veloxis Pharmaceuticals
Now you can see the different ways that different formulations are released and absorbed in the gastrointestinal system. You’ll also have the opportunity to explore comparative pharmacokinetic results in rapid metabolizers, efficacy data over 2 years, and safety information.
|
|
Journal of Heart and Lung Transplantation
Combined heart-lung transplantation is the optimal treatment option for many patients with end-stage heart failure and fixed severe pulmonary hypertension. It offers the only possibility of long-term survival and a return to a normal quality of life. Unfortunately, it is rarely performed due to donor organ allocation policies. Researchers present the case of a critically ill 24-year-old man, who after waiting over 100 days in-hospital on the urgent transplant list, deteriorated further and underwent the first successful heart-lung transplant with organs from a donation after circulatory death donor.
READ MORE
Brigham and Women's Hospital via Medical Xpress
Despite the limited supply of organs available for patients on waitlists for transplantation, organs from older, deceased donors are frequently discarded or not utilized. Available older organs have the potential to close the gap between demand and supply that is responsible for the very long wait-times that lead to many patients not surviving the time it takes for an organ to become available.
READ MORE
Advertisement
Veloxis Pharmaceuticals
Did you know there’s a transplant support system to help patients and providers with best-in-class assistance and resources? This ongoing support system assists with benefit investigation, prior authorization assistance, coordination with specialty pharmacies, prescription fulfillment navigation, and CoverMyMeds® access. There’s also a $0 co-pay card to overcome financial barriers.
Find out more
|
Clinical Infectious Diseases
Successful solid organ transplantation reflects meticulous attention to the details of immunosuppression, balancing risks for graft rejection against risks for infection. The "net state of immune suppression" is a conceptual framework of all factors contributing to infectious risk.
READ MORE
Clinical Transplantation
Pancreas transplant longevity is limited by immune rejection, which is diagnosed by graft biopsy using the Banff Classification. The histological criteria for antibody‐mediated rejection are poorly reproducible and inconsistently associated with outcome. Researchers hypothesized that a 34‐gene set associated with antibody‐mediated rejection in other solid organ transplants could improve diagnosis in pancreas grafts.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
